{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:50:25Z","timestamp":1768899025037,"version":"3.49.0"},"reference-count":90,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2014,12,23]]},"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To identify predictors of response to tumor necrosis factor (TNF) antagonists in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Systematic review and meta-analysis of clinical trials and observational studies based on a systematic search. Meta-analyses of similar observations were performed using random effects computing summary OR. Heterogeneity was tested using I<jats:sup>2<\/jats:sup>, and risks of bias using funnel plots and the Egger test. Meta-regression was used to explore causes of heterogeneity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The electronic search captured 1340 references and 217 abstracts. 17 additional articles were identified after searching by hand. A total of 59 articles meet the purpose of the study and were reviewed. 37 articles (33 studies) included 6736 patients with AS and 23 articles (22 studies) included 4034 patients with PsA. 1 article included data on AS and PsA. Age (OR (95% CI) 0.91 (0.84 to 0.99), I<jats:sup>2<\/jats:sup>=84.1%), gender (1.57 (1.10 to 2.25), I<jats:sup>2<\/jats:sup>=0.0%), baseline BASDAI (1.31 (1.09 to 1.57), I<jats:sup>2<\/jats:sup>=0.0%), baseline BASFI (0.86 (0.79 to 0.93), I<jats:sup>2<\/jats:sup>=24.9%), baseline dichotomous C reactive protein (CRP) (2.14 (1.71 to 2.68), I<jats:sup>2<\/jats:sup>=22.3%) and human leucocyte antigen B27 (HLA-B27) (1.81 (1.35 to 2.42), I<jats:sup>2<\/jats:sup>=0.0%) predict BASDAI50 response in AS. No factor was identified as a source of heterogeneity. Only meta-analysis of baseline BASFI showed risk of publication bias (Egger test, p=0.004). Similar results were found for ASAS criteria response. No predictors of response were identified in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Young age, male sex, high baseline BASDAI, low baseline BASFI, high baseline CRP and HLA-B27 predict better response to TNF antagonists in AS but not in PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2014-000017","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T04:35:58Z","timestamp":1424320558000},"page":"e000017","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":94,"title":["Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis"],"prefix":"10.1136","volume":"1","author":[{"given":"Jose Ramon","family":"Maneiro","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Souto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Salgado","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mera","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain"},{"name":"Department of Medicine, Medical School, Universidad de Santiago, Santiago, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J","family":"Gomez-Reino","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain"},{"name":"Department of Medicine, Medical School, Universidad de Santiago, Santiago, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"key":"2025090312333982000_1.1.e000017.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2025090312333982000_1.1.e000017.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"2025090312333982000_1.1.e000017.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"2025090312333982000_1.1.e000017.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090312333982000_1.1.e000017.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2025090312333982000_1.1.e000017.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025090312333982000_1.1.e000017.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2025090312333982000_1.1.e000017.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"2025090312333982000_1.1.e000017.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089276"},{"key":"2025090312333982000_1.1.e000017.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2010.11.032"},{"key":"2025090312333982000_1.1.e000017.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"2025090312333982000_1.1.e000017.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.34627"},{"key":"2025090312333982000_1.1.e000017.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"2025090312333982000_1.1.e000017.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken002"},{"key":"2025090312333982000_1.1.e000017.15","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312333982000_1.1.e000017.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081096"},{"key":"2025090312333982000_1.1.e000017.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094730"},{"key":"2025090312333982000_1.1.e000017.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.11.007"},{"key":"2025090312333982000_1.1.e000017.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"2025090312333982000_1.1.e000017.20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200603210-00010"},{"key":"2025090312333982000_1.1.e000017.21","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025090312333982000_1.1.e000017.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025090312333982000_1.1.e000017.23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025090312333982000_1.1.e000017.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025090312333982000_1.1.e000017.25","unstructured":"Department of Health & Human Services. Food & Drug Administration. 103795\/5123, Etanercept in Ankylosing Spondylitis. Medical Review. 2003. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/103795\u20135123_Enbrel_medr.pdf"},{"key":"2025090312333982000_1.1.e000017.26","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"2025090312333982000_1.1.e000017.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101128"},{"key":"2025090312333982000_1.1.e000017.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"2025090312333982000_1.1.e000017.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq129"},{"key":"2025090312333982000_1.1.e000017.30","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090312333982000_1.1.e000017.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.24838"},{"key":"2025090312333982000_1.1.e000017.32","first-page":"S204","article-title":"Predictors of ASDAS major improvement in patients with ankylosing spondylitis receiving their first TNF inhibitor. Results rrom a longitudinal observational study","volume":"63","author":"Fagerli","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025090312333982000_1.1.e000017.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes057"},{"key":"2025090312333982000_1.1.e000017.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"2025090312333982000_1.1.e000017.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.23606"},{"key":"2025090312333982000_1.1.e000017.36","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0434-8"},{"key":"2025090312333982000_1.1.e000017.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2025090312333982000_1.1.e000017.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.20870"},{"key":"2025090312333982000_1.1.e000017.39","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20258"},{"key":"2025090312333982000_1.1.e000017.40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep422"},{"key":"2025090312333982000_1.1.e000017.41","first-page":"2078","article-title":"C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis","volume":"34","author":"Luc","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090312333982000_1.1.e000017.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065052"},{"key":"2025090312333982000_1.1.e000017.43","doi-asserted-by":"publisher","DOI":"10.3109\/03009741003781969"},{"key":"2025090312333982000_1.1.e000017.44","doi-asserted-by":"publisher","DOI":"10.1186\/ar3350"},{"key":"2025090312333982000_1.1.e000017.45","first-page":"638","article-title":"Metalloproteinase-3 (MMP-3) is a predictor for anti-TNF-alpha response in patients with ankylosing spondylitis (AS)","volume":"30","author":"Navarro-Compan","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312333982000_1.1.e000017.46","doi-asserted-by":"publisher","DOI":"10.1186\/ar3841"},{"key":"2025090312333982000_1.1.e000017.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138883"},{"key":"2025090312333982000_1.1.e000017.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.08.005"},{"key":"2025090312333982000_1.1.e000017.49","first-page":"641","article-title":"Predictive factors of response at 12 weeks in patients with ankylosing spondylitis starting biological therapies\u2014results from the portuguese register\u2014Reuma.Pt","volume":"30","author":"Ramiro","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312333982000_1.1.e000017.50","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2025090312333982000_1.1.e000017.51","first-page":"744","article-title":"Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS)","volume":"26","author":"Rudwaleit","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312333982000_1.1.e000017.52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2025090312333982000_1.1.e000017.53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073098"},{"key":"2025090312333982000_1.1.e000017.54","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel175"},{"key":"2025090312333982000_1.1.e000017.55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200358"},{"key":"2025090312333982000_1.1.e000017.56","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006916"},{"key":"2025090312333982000_1.1.e000017.57","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.133"},{"key":"2025090312333982000_1.1.e000017.58","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"2025090312333982000_1.1.e000017.59","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071605"},{"key":"2025090312333982000_1.1.e000017.60","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148890"},{"key":"2025090312333982000_1.1.e000017.61","unstructured":"Chandran V , Shen H , Pollock R , et al . Soluble biomarkers predict response to anti-tumour necrosis factor (TNF) therapy in psoriatic arthritis (PsA). Arthritis Rheum. 2009; Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 09 Atlanta, GA United States. Conference Start: 20101106 Conference End: 20101111. Conference Publication: (var.pagings). 60:1778."},{"key":"2025090312333982000_1.1.e000017.62","first-page":"23","article-title":"Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment","volume":"30","author":"Chimenti","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312333982000_1.1.e000017.63","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711"},{"key":"2025090312333982000_1.1.e000017.64","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq091"},{"key":"2025090312333982000_1.1.e000017.65","doi-asserted-by":"publisher","DOI":"10.1186\/ar3049"},{"key":"2025090312333982000_1.1.e000017.66","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"2025090312333982000_1.1.e000017.67","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025090312333982000_1.1.e000017.68","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060079"},{"key":"2025090312333982000_1.1.e000017.69","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.715186"},{"key":"2025090312333982000_1.1.e000017.70","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110763"},{"key":"2025090312333982000_1.1.e000017.71","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110242"},{"key":"2025090312333982000_1.1.e000017.72","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"2025090312333982000_1.1.e000017.73","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"2025090312333982000_1.1.e000017.74","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"#cr-split#-2025090312333982000_1.1.e000017.75.1","unstructured":"Marotta A , Van Kuijk AW , Maksymowych WP , et al . 14-3-3 Eta is a modifiable serum biomarker that marks adalimumab response in psoriatic arthritis. Arthritis Rheum. 2012 October"},{"key":"#cr-split#-2025090312333982000_1.1.e000017.75.2","unstructured":"Conference: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012 Washington, DC United States. Conference Start: 20121109 Conference End: 20121114. Conference Publication: (var.pagings). 64:S247."},{"key":"2025090312333982000_1.1.e000017.76","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025090312333982000_1.1.e000017.77","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110980"},{"key":"2025090312333982000_1.1.e000017.78","doi-asserted-by":"publisher","DOI":"10.1186\/ar3021"},{"key":"2025090312333982000_1.1.e000017.79","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085951"},{"key":"2025090312333982000_1.1.e000017.80","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111856"},{"key":"2025090312333982000_1.1.e000017.81","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201697"},{"key":"2025090312333982000_1.1.e000017.82","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181ca4a2a"},{"key":"2025090312333982000_1.1.e000017.83","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.7430"},{"key":"2025090312333982000_1.1.e000017.84","first-page":"862","article-title":"Identification of cytokines that might enhance the promoter activity of HLA-B27","volume":"35","author":"Zhao","year":"2008","journal-title":"J Rheumatol"},{"key":"2025090312333982000_1.1.e000017.85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00984.x"},{"key":"2025090312333982000_1.1.e000017.86","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1582-4934.2008.00310.x","article-title":"TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats","volume":"13","author":"Milia","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2025090312333982000_1.1.e000017.87","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2025090312333982000_1.1.e000017.88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480030052036"},{"key":"2025090312333982000_1.1.e000017.89","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO;2-G"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2014-000017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:33:50Z","timestamp":1756928030000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2014-000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,2,18]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1136\/rmdopen-2014-000017"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2014-000017","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}